Calithera Biosciences (NASDAQ: CALA) to announce new clinical data from the solid tumor expansion cohorts of its lead anti-cancer therapeutic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Leerink Partners Reiterates Outperform on Calithera Biosciences (CALA) Following 3Q November 10, 2015 7:00 AM Calithera to Present New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at the 2015 AACR-NCI-EORTC International ConferenceNovember 8, 2015 12:15 PM Calithera Presents Preclinical Study Findings for CB-1158 at the 2015 AACR-NCI-EORTC International ConferenceNovember 6, 2015 9:01 AM Calithera Announces Multiple Abstracts Selected for Presentation at the 57th American Society of Hematology Annual MeetingNovember 5, 2015 9:06 AM